Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
UBX Stock Summary
In the News

Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).

Unity Biotechnology (UBX) Stock Pops on Positive Study Data
Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat patients dealing with diabetic macular edema (DME).

Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results
A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials.

All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Three Best Anti-Aging Stocks to Buy in September
Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.

UNITY Biotechnology to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Hot Penny Stocks to Add to Your Watchlist Right Now
Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?
Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022. That report starts with the company's current cash position sitting at $64.5 million.
UBX Financial details
UBX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0.86 | 0.02 | |
Net income per share | -27.02 | -17.16 | -18.06 | -10.76 | -6.08 | |
Operating cash flow per share | -20.03 | -16.6 | -15.4 | -8.07 | -5.37 | |
Free cash flow per share | -20.48 | -16.96 | -15.53 | -8.11 | -5.38 | |
Cash per share | 60.54 | 29.22 | 19.21 | 15.78 | 9.98 | |
Book value per share | 56.84 | 27.67 | 16.29 | 10.67 | 7.04 | |
Tangible book value per share | 56.84 | 27.67 | 16.29 | 10.67 | 7.04 | |
Share holders equity per share | 56.84 | 27.67 | 16.29 | 10.67 | 7.04 | |
Interest debt per share | 1.17 | 0 | 12.74 | 9.81 | 5.36 | |
Market cap | 459.67M | 314.53M | 266.53M | 81.49M | 26.01M | |
Enterprise value | 444.39M | 277.06M | 307.7M | 100.14M | 60.64M | |
P/E ratio | -6.02 | -4.2 | -2.9 | -1.36 | -0.45 | |
Price to sales ratio | 0 | 0 | 0 | 17.03 | 110.23 | |
POCF ratio | -8.12 | -4.34 | -3.4 | -1.81 | -0.51 | |
PFCF ratio | -7.94 | -4.25 | -3.37 | -1.8 | -0.51 | |
P/B Ratio | 2.86 | 2.61 | 3.22 | 1.37 | 0.39 | |
PTB ratio | 2.86 | 2.61 | 3.22 | 1.37 | 0.39 | |
EV to sales | 0 | 0 | 0 | 20.93 | 256.94 | |
Enterprise value over EBITDA | -6.31 | -3 | -3.42 | -1.74 | -1.08 | |
EV to operating cash flow | -7.85 | -3.83 | -3.93 | -2.22 | -1.19 | |
EV to free cash flow | -7.68 | -3.74 | -3.9 | -2.21 | -1.19 | |
Earnings yield | -0.17 | -0.24 | -0.34 | -0.74 | -2.22 | |
Free cash flow yield | -0.13 | -0.24 | -0.3 | -0.56 | -1.97 | |
Debt to equity | 0 | 0 | 0.77 | 0.87 | 0.71 | |
Debt to assets | 0 | 0 | 0.41 | 0.41 | 0.38 | |
Net debt to EBITDA | 0.22 | 0.41 | -0.46 | -0.32 | -0.61 | |
Current ratio | 10.43 | 7.52 | 6.97 | 5.45 | 4.92 | |
Interest coverage | -23.99 | 0 | -72.7 | -17.84 | -16.18 | |
Income quality | 0.74 | 0.88 | 0.83 | 0.74 | 0.85 | |
Dividend Yield | 0.13 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.8 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 4.82 | 88.77 | |
Research and developement to revenue | 0 | 0 | 0 | 8.03 | 156.18 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.02 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.04 | -0.41 | |
Capex to depreciation | -0.58 | -0.6 | -0.19 | -0.07 | -0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 2.41 | 39.74 | |
Graham number | 185.91 | 103.37 | 81.37 | 50.82 | 31.04 | |
ROIC | -0.51 | -0.68 | -0.51 | -0.4 | -0.39 | |
Return on tangible assets | -0.42 | -0.5 | -0.59 | -0.48 | -0.46 | |
Graham Net | 53.22 | 22.23 | 4.77 | 4.11 | 3.93 | |
Working capital | 156.38M | 112.27M | 86.4M | 73.89M | 76.92M | |
Tangible asset value | 160.69M | 120.71M | 82.88M | 59.57M | 66.85M | |
Net current asset value | 152.28M | 98.97M | 27.43M | 25.36M | 39.03M | |
Invested capital | 0 | 0 | 0.77 | 0.87 | 0.71 | |
Average receivables | 691K | 0 | 0 | 0 | 0 | |
Average payables | 3.61M | 5.02M | 3.87M | 2.27M | 1.89M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.48 | -0.62 | -1.11 | -1.01 | -0.86 | |
Capex per share | -0.45 | -0.36 | -0.13 | -0.03 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.03 | 0 | -0.02 | 0 | 0 | |
Net income per share | -2.02 | -1.42 | -0.97 | -0.84 | -0.85 | |
Operating cash flow per share | -2.14 | -1.08 | -0.73 | -0.79 | -0.77 | |
Free cash flow per share | -2.16 | -1.08 | -0.74 | -0.79 | -0.77 | |
Cash per share | 9.32 | 9.82 | 6.7 | 5.83 | 4.79 | |
Book value per share | 5.77 | 7.8 | 4.73 | 4.1 | 3.42 | |
Tangible book value per share | 5.77 | 7.8 | 4.73 | 4.1 | 3.42 | |
Share holders equity per share | 5.77 | 7.8 | 4.73 | 4.1 | 3.42 | |
Interest debt per share | 7.11 | 4.83 | 3.42 | 3.34 | 3.05 | |
Market cap | 39.06M | 39.78M | 38.75M | 23.33M | 36.79M | |
Enterprise value | 67.94M | 65.04M | 73.37M | 47.19M | 60.75M | |
P/E ratio | -0.7 | -0.7 | -0.7 | -0.48 | -0.75 | |
Price to sales ratio | 165.49 | 0 | -164.17 | 0 | 0 | |
POCF ratio | -2.63 | -3.66 | -3.74 | -2.06 | -3.32 | |
PFCF ratio | -2.61 | -3.65 | -3.72 | -2.06 | -3.32 | |
P/B Ratio | 0.98 | 0.51 | 0.58 | 0.4 | 0.74 | |
PTB ratio | 0.98 | 0.51 | 0.58 | 0.4 | 0.74 | |
EV to sales | 287.9 | 0 | -310.88 | 0 | 0 | |
Enterprise value over EBITDA | -5.84 | -5.28 | -5.57 | -4.78 | -5.57 | |
EV to operating cash flow | -4.58 | -5.99 | -7.08 | -4.17 | -5.48 | |
EV to free cash flow | -4.53 | -5.96 | -7.05 | -4.17 | -5.48 | |
Earnings yield | -0.36 | -0.36 | -0.36 | -0.52 | -0.33 | |
Free cash flow yield | -0.38 | -0.27 | -0.27 | -0.49 | -0.3 | |
Debt to equity | 1.21 | 0.61 | 0.71 | 0.8 | 0.87 | |
Debt to assets | 0.5 | 0.35 | 0.38 | 0.41 | 0.43 | |
Net debt to EBITDA | -2.48 | -2.05 | -2.63 | -2.42 | -2.2 | |
Current ratio | 4.13 | 6.12 | 4.92 | 4 | 3.28 | |
Interest coverage | -13.71 | -15.16 | -14.06 | -10.63 | -12.22 | |
Income quality | 1.13 | 0.79 | 0.73 | 1.04 | 0.91 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 20.94 | 0 | -22.37 | 0 | 0 | |
Research and developement to revenue | 32 | 0 | -36.59 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.64 | 0 | 0.16 | 0 | 0 | |
Capex to depreciation | -0.25 | -0.09 | -0.09 | 0 | 0 | |
Stock based compensation to revenue | 9.53 | 0 | -9.57 | 0 | 0 | |
Graham number | 16.21 | 15.78 | 10.17 | 8.82 | 8.07 | |
ROIC | -0.11 | -0.09 | -0.1 | -0.09 | -0.11 | |
Return on tangible assets | -0.14 | -0.1 | -0.11 | -0.11 | -0.12 | |
Graham Net | 0.99 | 4.08 | 2.64 | 1.94 | 1.36 | |
Working capital | 51.4M | 85.95M | 76.92M | 64.8M | 50.74M | |
Tangible asset value | 39.93M | 78.57M | 66.85M | 58.63M | 49.41M | |
Net current asset value | 10.16M | 44.9M | 39.03M | 30.75M | 21.37M | |
Invested capital | 1.21 | 0.61 | 0.71 | 0.8 | 0.87 | |
Average receivables | 0 | 0 | 0 | 0 | 871.5K | |
Average payables | 2.38M | 1.94M | 2.12M | 1.63M | 1.46M | |
Average inventory | 0 | 0 | 0 | 0 | 880.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.35 | -0.18 | -0.21 | -0.21 | -0.25 | |
Capex per share | -0.02 | 0 | 0 | 0 | 0 |
UBX Frequently Asked Questions
What is Unity Biotechnology, Inc. stock symbol ?
Unity Biotechnology, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol UBX
What is Unity Biotechnology, Inc. stock quote today ?
Unity Biotechnology, Inc. stock price is $2.4159 today.
Is Unity Biotechnology, Inc. stock public?
Yes, Unity Biotechnology, Inc. is a publicly traded company.